Healthcare / Medical Instruments & SuppliesNasdaqGM
$26.48
-1.19 (-4.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.3M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
72.0x
↑ROE
-2.3%
↓Gross Margin
75.0%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+15.3%
FCF CAGR
—
FCF margin
7.9%
FCF / Net income
-3.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $534.5M · net income $-11.4M · FCF $42.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $534.5M | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M | $206.5M | $230.8M | $201.6M | $174.7M | $155.1M | $129.8M | $107.5M | $81.9M | $70.2M | $64.4M | $59.0M | $54.5M |
| Net Income | $-11.4M | $-11.4M | $-44.7M | $-30.4M | $-46.5M | $50.2M | $-48.2M | $-35.2M | $-21.1M | $-26.9M | $-33.3M | $-27.2M | $-16.2M | $-11.5M | $-7.5M | $-5.5M | $-3.8M | $-16.5M |
| EBITDA | $16.2M | $16.2M | $-18.5M | $-8.1M | $-29.5M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.24 | -0.24 | -0.95 | -0.66 | -1.02 | 1.09 | -1.14 | -0.94 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 75.0% | 75.0% | 74.7% | 75.2% | 74.4% | 75.0% | 72.3% | 73.8% | 73.0% | 72.2% | 71.6% | 71.6% | 70.5% | 72.7% | 71.2% | 73.0% | 76.9% | 76.6% |
| Operating Margin | -1.8% | -1.8% | -8.6% | -6.7% | -12.9% | 20.1% | -21.4% | -14.4% | -8.5% | -14.3% | -20.1% | -20.6% | -15.2% | -13.3% | -10.2% | -7.3% | -5.4% | -28.4% |
| Net Margin | -2.1% | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% | -15.2% | -10.5% | -15.4% | -21.5% | -21.0% | -15.1% | -14.0% | -10.7% | -8.5% | -6.4% | -30.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.15 | 0.15 | 0.16 | 0.16 | 0.16 | 0.12 | 0.13 | 0.24 | 0.14 | 0.15 | 0.14 | — | — | — | — | — | — | — |
| Current Ratio | 4.29 | 4.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $42.3M | $42.3M | $-11.3M | $-37.5M | $-39.0M | $-23.5M | $-25.1M | $-28.0M | $-10.4M | $-15.3M | $-22.8M | $-21.3M | — | $-8.1M | $-4.9M | $-3.5M | $-1.8M | $-940511.00 |
| Returns | ||||||||||||||||||
| ROE | -2.3% | -2.3% | -9.7% | -6.5% | -10.2% | 10.4% | -11.7% | -14.2% | -8.5% | -16.7% | -19.8% | -14.6% | -12.2% | -15.8% | -60.3% | -34.9% | -22.7% | -96.5% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | 72.04 | 72.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.57 | 2.57 | 3.26 | 3.28 | 4.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 14.9% | 14.9% | 16.5% | 20.8% | — | 32.8% | -10.5% | 14.5% | 15.4% | 12.6% | 19.5% | 20.8% | 31.2% | 16.6% | 9.1% | 9.1% | 8.2% | — |
| EPS Growth | 74.7% | 74.7% | -43.9% | 35.3% | — | 195.6% | -21.3% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.95 → -0.24
Residual
-23.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.